Press "Enter" to skip to content

Merck, Pfizer drug combo extends kidney cancer survival – study

A combination of Merck & Co’s immunotherapy Keytruda and Pfizer Inc’s Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

Original source: https://health.economictimes.indiatimes.com/news/pharma/merck-pfizer-drug-combo-extends-kidney-cancer-survival-study/68031913?utm_source=RSS&utm_medium=ETRSS

Also Read:   Chinese province reports 11 new virus cases from Iran flights: state media